Koru Medical Systems, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Koru Medical Systems Inc. announced a 22.1% increase in net revenues for Q1 2026, driven by strong performance in its core domestic and international businesses, alongside significant growth in its pharma services segment.
NASDAQ
KORU Medical Systems reported a significant reduction in net loss for Q3 2025, driven by robust international core revenue growth despite domestic declines.
NASDAQ
KORU Medical Systems announced a significant increase in net revenues and a substantial reduction in net loss for the second quarter and first half of 2025, driven by core business expansion and pharma services.
NASDAQ
KORU Medical Systems reports a 17.5% increase in net revenues for the first quarter of 2025, driven by growth in domestic and international core businesses.
NASDAQ
Koru Medical Systems saw a 16.8% increase in revenue in the third quarter of 2024, driven by growth in both its core business and novel therapies segment.
NASDAQ
KORU Medical Systems saw a significant 21.5% increase in revenue in the second quarter of 2024, driven by growth in both core and novel therapies businesses.
NASDAQ
KORU Medical Systems saw a 10.9% increase in net revenue in the first quarter of 2024, primarily driven by growth in its core domestic and international businesses.